Society of Nuclear Medicine & Molecular Imaging: Travel Considerations Specified for Lu-177-DOTATATE Radiation Therapy Patients
April 25, 2020
April 25, 2020
RESTON, Virginia, April 25 -- The Society of Nuclear Medicine and Molecular Imaging issued the following news release:
A team of researchers and patient advocates has addressed the challenges related to traveling after receiving 177Lu-DOTATATE radiation therapy in a study published in The Journal of Nuclear Medicine. Due to the residual radiation activity of 177Lu-DOTATATE, neuroendocrine tumor patients have experienced travel delays at U.S. ports of entry. It is recommended that pa . . .
A team of researchers and patient advocates has addressed the challenges related to traveling after receiving 177Lu-DOTATATE radiation therapy in a study published in The Journal of Nuclear Medicine. Due to the residual radiation activity of 177Lu-DOTATATE, neuroendocrine tumor patients have experienced travel delays at U.S. ports of entry. It is recommended that pa . . .